Literature DB >> 25997029

Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study.

Marianna Fontana1, Sanjay M Banypersad1, Thomas A Treibel1, Amna Abdel-Gadir1, Viviana Maestrini1, Thirusha Lane1, Janet A Gilbertson1, David F Hutt1, Helen J Lachmann1, Carol J Whelan1, Ashutosh D Wechalekar1, Anna S Herrey1, Julian D Gillmore1, Philip N Hawkins1, James C Moon1.   

Abstract

PURPOSE: To investigate cardiac magnetic resonance (MR) imaging measurements of extracellular volume (ECV) and total cell volume in immunoglobulin light-chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) in order to evaluate the amyloid and myocyte volumes.
MATERIALS AND METHODS: All ethics were approved, and participants provided written informed consent. Of the 257 subjects who were recruited, 92 had AL (mean age, 62 years ± 10), 44 had mutant ATTR (mean age, 68 years ± 10), and 66 had wild-type ATTR (mean age, 75 years ± 7). In addition, eight healthy subjects with ATTR mutations (mean age, 47 years ± 6) and 47 healthy volunteers (mean age, 45 years ± 15) participated. All participants underwent equilibrium contrast material-enhanced cardiac MR imaging. ECV and total cell volume were measured in the heart. T test, χ(2), and one-way analysis of variance with posthoc Bonferroni correction were used.
RESULTS: Both the left ventricular indexed mass and ECV were elevated in patients with amyloidosis. For left ventricular indexed mass, mean AL was 107 g/m(2) ± 30; mean mutant ATTR was 137 g/m(2) ± 29; and mean wild-type ATTR was 133 g/m(2) ± 27 versus 65 g/m(2) ± 15 in healthy subjects (P < .0001 for all measures). For ECV, mean AL was 0.54 ± 0.07, mean mutant ATTR was 0.60 ± 0.07, and mean wild-type ATTR was 0.57 ± 0.06 versus 0.27 ± 0.03 in healthy subjects (P < .0001 for all measures). Patients with ATTR had a higher total cell volume than did healthy subjects (mean, 53 mL/m(2) ± 12 vs 45 mL/m(2) ± 11; P = .001), but in patients with AL, total cell volume was normal (mean, 47 mL/m(2) ± 17 vs 45 mL/m(2) ± 11; P > .99). The result is that, in patients with AL, all of the increase in left ventricular indexed mass is extracellular volume, whereas in patients with ATTR, the increase is extracellular, with an additional 18% increase in the intracellular space.
CONCLUSION: Quantification of ECV measures cardiac amyloid deposition in both types of amyloidosis and shows that amyloid deposition is more extensive in patients with ATTR than in those with AL; however, ATTR is associated with higher cell volume, which suggests concomitant cell hypertrophy. © RSNA, 2015

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25997029     DOI: 10.1148/radiol.2015141744

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  45 in total

Review 1.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

Authors:  Praveen G Ranganath; Albree Tower-Rader
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 2.  Role of Imaging in Evaluating Infiltrative Heart Disease.

Authors:  Sanjay Divakaran; Avinainder Singh; Bradley Collins; Tomas Vita; Rodney H Falk; Marcelo F Di Carli; Ron Blankstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-01

Review 3.  Microvascular dysfunction in infiltrative cardiomyopathies.

Authors:  Ornella Rimoldi; Francesco Maranta
Journal:  J Nucl Cardiol       Date:  2017-07-11       Impact factor: 5.952

4.  Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy.

Authors:  Seitaro Oda; Daisuke Utsunomiya; Kosuke Morita; Takeshi Nakaura; Hideaki Yuki; Masafumi Kidoh; Kenichiro Hirata; Narumi Taguchi; Noriko Tsuda; Shinya Shiraishi; Tomohiro Namimoto; Kyoko Hirakawa; Seiji Takashio; Yasuhiro Izumiya; Megumi Yamamuro; Seiji Hokimoto; Kenichi Tsujita; Mitsuharu Ueda; Taro Yamashita; Yukio Ando; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2017-05-05       Impact factor: 5.315

5.  Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Authors:  Paolo Milani; Angela Dispenzieri; Christopher G Scott; Morie A Gertz; Stefano Perlini; Roberta Mussinelli; Martha Q Lacy; Francis K Buadi; Shaji Kumar; Mathew S Maurer; Giampaolo Merlini; Suzanne R Hayman; Nelson Leung; David Dingli; Kyle W Klarich; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Patricia A Pellikka; Yi L Hwa; Stephen R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Martha Grogan
Journal:  Circ Cardiovasc Imaging       Date:  2018-05       Impact factor: 7.792

Review 6.  Clinical applications of multiparametric CMR in left ventricular hypertrophy.

Authors:  Sabrina Nordin; Luke Dancy; James C Moon; Daniel M Sado
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-03       Impact factor: 2.357

Review 7.  How to Image Cardiac Amyloidosis: A Practical Approach.

Authors:  Sharmila Dorbala; Sarah Cuddy; Rodney H Falk
Journal:  JACC Cardiovasc Imaging       Date:  2019-10-11

Review 8.  Cardiac amyloidosis.

Authors:  Ana Martinez-Naharro; Philip N Hawkins; Marianna Fontana
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

9.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis.

Authors:  João L Cavalcante; Shasank Rijal; Islam Abdelkarim; Andrew D Althouse; Michael S Sharbaugh; Yaron Fridman; Prem Soman; Daniel E Forman; John T Schindler; Thomas G Gleason; Joon S Lee; Erik B Schelbert
Journal:  J Cardiovasc Magn Reson       Date:  2017-12-07       Impact factor: 5.364

Review 10.  Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.

Authors:  David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer
Journal:  Can J Cardiol       Date:  2016-05-13       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.